相关实验视频

Updated: Jul 26, 2025

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

甲胺抑制ZIKV复制,并减轻微质细胞中病毒诱导的炎症反应

Xiaofang Wang¹, Hui Wang², Panpan Yi³

¹Department of Infectious Disease, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan 410005, China; Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

International immunopharmacology

|June 21, 2023

概括

甲福明可降低寨卡病毒 (ZIKV) 复制和微质中的炎症. 这种糖尿病药物可能提供一种新的策略来对抗ZIKV神经炎症,影响干扰素通路.

科学领域:

神经科学是一个神经科学.
病毒学病毒学
免疫学免疫学免疫学

背景情况:

寨卡病毒 (ZIKV) 构成重大公共卫生风险,可能导致严重的神经损伤,如小头症.
一种常见的糖尿病药物梅特福明正在研究其抗病毒性质,但其与ZIKV的相互作用尚不清楚.

研究的目的:

为了研究甲胺对微质中ZIKV感染的影响.
阐明梅特福林对ZIKV的潜在抗病毒活性背后的机制.

主要方法:

利用光ZIKV,流细胞计和免疫光成像来评估微质中的ZIKV感染.
进行RNA测序 (RNA-Seq) 和定量逆转录PCR (qRT-PCR) 来分析基因表达变化.

主要成果:

甲福明抑制了微质中的ZIKV复制,但没有影响病毒的进入或细胞化.
甲胺剂量和时间依赖性降低了ZIKV诱导的炎症反应.
甲胺治疗上调I型和III型干扰素 (IFN),同时降低干扰素刺激的特定基因 (ISG).

结论:

甲胺调节多个细胞通路,包括干扰素信号传递,以抑制微质中的ZIKV感染.
这些发现表明甲胺是ZIKV感染的潜在治疗剂,特别是在神经学上.

关键词:

炎症炎症是一种炎症.干扰素干扰素干扰素甲胺是一种甲胺.微质细胞中的微质细胞病毒感染是一种病毒感染.在ZIKVV,你会发现.

更多相关视频

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...